KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

Abstract

The KRAS mutation remains the most common driver mutation in patients with non‐small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS‐RAF‐MEK‐ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.